Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

2.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

3.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

4.

RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung

5.

Screening tests that are non-invasive show promise in detecting colorectal cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot